Lyra Therapeutics
- Company typePublic
- Founded2015
- HeadquartersWatertown, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Lyra Therapeutics firmographics
Firmographics- Name
- Lyra Therapeutics
- Legal name
- Lyra Therapeutics, Inc.
- Website
- https://lyratherapeutics.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Closed
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Lyra Therapeutics industry classification
Industry- Product category
- ENT Therapeutics
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)
- akta.pro secondary industry
- Rhinology & Sinus Surgery (HLAKAMAD)
Keywords
Where Lyra Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Watertown
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Lyra Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others
Revenue model
- Pharmaceutical product sales: Pre-revenue clinical-stage biotechnology company developing biopharmaceutical products (LYR-210 and LYR-220) for chronic rhinosinusitis. Future revenue expected from product commercialization following FDA approval.
- NDA submission and commercialization: Company completed ENLIGHTEN 2 Phase 3 trial and intends to seek NDA submission for LYR-210 for treatment of chronic rhinosinusitis
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Lyra Therapeutics product offering
Product offeringCore offering
Lyra Therapeutics develops bioabsorbable drug-eluting nasal mesh products (LYR-210 and LYR-220) built on its proprietary XTreo™ platform to deliver up to six months of continuous mometasone furoate anti-inflammatory therapy directly to sinonasal tissues. The products are designed for single in-office administration by ENT specialists to treat adult chronic rhinosinusitis (CRS) patients who have either failed current medical management (LYR-210) or have persistent disease after prior sinus surgery (LYR-220).
Product overview
Lyra Therapeutics is a clinical-stage biotechnology company with two bioabsorbable nasal mesh product candidates built on its proprietary XTreo™ drug delivery platform. Lead product LYR-210 (Phase 3) targets surgically-naïve CRS patients without nasal polyps, while second product LYR-220 (Phase 2 completed) is sized for CRS patients with post-surgical anatomy. Both products deliver continuous mometasone furoate anti-inflammatory therapy for up to six months via a single in-office administration, addressing the treatment gap for the approximately 4 million CRS patients who fail medical management.
Differentiator
Problem solved
Functional benefit
Products and services
- LYR-210 Bioabsorbable nasal mesh designed to deliver up to six months of continuous mometasone furoate anti-inflammatory therapy to sinonasal passages for treatment of chronic rhinosinusitis (CRS) in adult patients who have failed current medical management. Administered via brief in-office procedure by ENT specialists. Was in Phase 3 ENLIGHTEN clinical development.
- LYR-220 Bioabsorbable nasal mesh (larger than LYR-210) designed to deliver up to six months of continuous mometasone furoate anti-inflammatory therapy for CRS patients with post-surgical anatomy (enlarged nasal cavity after prior sinus surgery). Administered via brief in-office procedure by ENT specialists. Completed Phase 2 BEACON trial.
Quantifiable outcome
- 14 million CRS patients in US; 4 million fail medical management
- +2 more outcomes
Companies that use Lyra Therapeutics
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Lyra Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Lyra Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- RVAC MedicinesminorRVAC Medicines (US), Inc. is the sublandlord for Lyra's office space at 880 Winter Street in Waltham, Massachusetts. Lyra received a default notice from RVAC regarding $484,431.92 in unpaid rent and agreed to a $2.1 million termination payment to end the sublease.
Scale indicators11 records
Recent moves10 records
Expansion highlights4 records
Lyra Therapeutics competitors and assessment
Company assessmentDirect peers
- Intersect ENT (Medtronic): Acquired by Medtronic in 2022, Intersect ENT developed PROPEL steroid-eluting sinus implants used by ENTs after sinus surgery. Directly comparable to Lyra's LYR-220, which targets the post-surgical CRS population with a bioabsorbable, drug-eluting nasal mesh delivering mometasone furoate.
- OptiNose: OptiNose develops nasal drug delivery products for ENT and respiratory conditions using its own Exhalation Delivery Systems platform. Like Lyra, it focuses on delivering proven drugs via novel nasal devices for chronic ENT/rhinosinusitis patients, and historically served as a direct competitor in targeted nasal delivery for CRS and related indications.
Broad incumbents
- GlaxoSmithKline: GSK markets Nasonex (mometasone furoate monohydrate) — the same off-patent corticosteroid used in Lyra's LYR-210/LYR-220. As a broad respiratory/ENT incumbent, GSK represents the entrenched mometasone spray baseline against which Lyra's sustained-release implant must demonstrate superiority.
- AstraZeneca: AstraZeneca markets Fasenra (benralizumab), a biologic approved for severe eosinophilic asthma with ongoing development in CRSwNP. As a broad respiratory player, AZ represents a major competitor and potential strategic acquirer of any late-stage CRS asset like Lyra's.
- Sanofi / Regeneron: Sanofi and Regeneron co-developed Dupixent (dupilumab), the first biologic approved for inadequately controlled CRS with nasal polyps — the same surgically-naïve CRS population Lyra's LYR-210 targets. Dupixent's biologic approval defines the competitive frontier for any new CRS therapy and is the most credible substitute for procedural implants.
Others
- Nemera: Nemera is a contract developer and manufacturer of nasal and pulmonary drug delivery devices, including unit-dose and multi-dose nasal spray pumps. It is a relevant ecosystem peer given Lyra's reliance on novel nasal mesh device manufacturing and supply chain know-how.
Emerging players
- Ocular Therapeutix: Ocular Therapeutix develops bioabsorbable hydrogel-based implants for sustained ocular drug delivery — same drug-device combination product paradigm that Lyra's XTreo mesh platform employs, just applied to a different anatomical site. Comparable technology category with similar regulatory pathway as a drug-device combination.
- Allakos: Allakos is a clinical-stage biotech developing therapeutics for inflammatory diseases including CRS with nasal polyps (CRSwNP). It targets a partially overlapping CRS subpopulation using a different mechanism (anti-Siglec-8 antibody lirentelimab), competing for the same severe CRS treatment paradigm that Lyra's LYR-210 aims to serve.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Lyra Therapeutics social profiles
Digital presenceLyra Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lyra Therapeutics leadership team
Management profileNumber of profiles
Profiles11 records
Lyra Therapeutics funding detail
Funding detailFunding overview
Funding rounds11 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lyra Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lyra Therapeutics
What does Lyra Therapeutics do?
Lyra Therapeutics develops bioabsorbable drug-eluting nasal mesh products (LYR-210 and LYR-220) built on its proprietary XTreo™ platform to deliver up to six months of continuous mometasone furoate anti-inflammatory therapy directly to sinonasal tissues. The products are designed for single in-office administration by ENT specialists to treat adult chronic rhinosinusitis (CRS) patients who have either failed current medical management (LYR-210) or have persistent disease after prior sinus surgery (LYR-220).
Is Lyra Therapeutics a public or private company?
Lyra Therapeutics is a public company. It is classified as public and is currently closed.
When was Lyra Therapeutics founded?
Lyra Therapeutics was founded in 2015. It employs 51 to 100 people.
Where is Lyra Therapeutics based?
Lyra Therapeutics is headquartered in Watertown, United States, in the North America region.
How does Lyra Therapeutics make money?
Two revenue lines are on record. Pharmaceutical product sales are the primary driver. The others are NDA submission and commercialization.
Who are Lyra Therapeutics's main competitors?
Direct peers on record are Intersect ENT (Medtronic) and OptiNose. Broad incumbents are GlaxoSmithKline, AstraZeneca and Sanofi / Regeneron. Nemera is listed as an others. Emerging players are Ocular Therapeutix and Allakos.
Does Lyra Therapeutics have an API?
No public API is recorded for Lyra Therapeutics.
What industry is Lyra Therapeutics in?
Lyra Therapeutics's product category is ENT Therapeutics. Its primary akta.pro industry code is HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices), with a secondary code of HLAKAMAD, Rhinology & Sinus Surgery. Its NAICS code is 5417 and its SIC code is 3841.